H.C. Wainwright lowered the firm’s price target on Kronos Bio to $2.25 from $2.50 and keeps a Buy rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRON:
- Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Kronos Bio’s Restructuring Risks: Cost Cuts Versus Operational Efficiency
- Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
- Kronos Bio reports Q4 EPS (43c), consensus (52c)
- KRON Earnings this Week: How Will it Perform?
Questions or Comments about the article? Write to editor@tipranks.com